Olivier Léger

Olivier Léger Email and Phone Number

Independent consultant in the field of Antibody Engineering @ Tridek-One
france, aquitaine, france
Olivier Léger's Location
Annecy, Auvergne-Rhône-Alpes, France, France
About Olivier Léger

• Experienced antibody engineer with over 30 years of accomplishments in research, research management, project management for discovery project teams, intellectual property, lead discovery and preclinical development. • Entrepreneur, a self-starter, flexible and very hands-on. • International experience having worked for biotechnology and pharmaceutical companies in the UK, France and Switzerland. • Co-inventor of emapalumab, anti-Interferon gamma fully human antibody, marketed a Gamifant and co-developed by NovImmune SA and Sobi™ for the treatment of primary haemophagocytic lymphohistiocytosis (HLH) • Co-inventor of avelumab, anti-PDL1 fully-human monoclonal antibody, marketed as Bavencio® and co-developed by EMD Serono and Pfizer for the treatment of cancer.• Co-inventor of natalizumab, a humanized monoclonal antibody, marketed as Tysabri® for the treatment of multiple sclerosis.• Co-inventor of sonelokimab an investigational anti-IL-17 A/F Nanobody®, which neutralizes both IL-17A and IL-17F. In 2023 MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results in hidradenitis suppurativa (HS).• Co-inventor of Foralumab (28F11-AE; NI-0401) a fully human monoclonal antibody that binds to CD3-epsilon is currently in clinical development by Tiziana Life Sciences• Co-founder and member of the board of Deeptope, an antibody characterization and optimization CRO. Providing solutions for epitope mapping, paratope mapping and lead optimization.• Co-founder and acting CSO of Kekkan Biologics, start-up incubated at SEMIA in Strasbourg. A spin-off from the laboratory of Dr. Gilles PAGES, University of Nice Cote d’Azur (Université de Nice Côte d’Azur) and the Institute for Research on Cancer and Aging (IRCAN).• Collaboration with start-up Stealth IO in Marseille• Scientific advisor for Biomunex Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of innovative bispecific antibody therapeutics, based on a proprietary platform, to address unmet medical needs in the treatment of cancer.• 40 patents, 18 scientific publications / book chapters 4• Expertise: antibody engineering technologies, group leader, drug discovery process for NBE,

Olivier Léger's Current Company Details
Tridek-One

Tridek-One

View
Independent consultant in the field of Antibody Engineering
france, aquitaine, france
Website:
tridekone.com
Employees:
3
Olivier Léger Work Experience Details
  • Tridek-One
    Vp Biologics Engineering
    Tridek-One Nov 2022 - Present
    Paris, Île-De-France, France
    View
  • Leger Consulting, Entreprise Individuelle
    Senior Consultant
    Leger Consulting, Entreprise Individuelle Nov 2013 - Present
    Annecy Area, France
    • Agreement for french "Crédit Impôt Recherche" (CIR) for 2017, 2018, 2019, 2020, 2021• Provide as a service the design of humanization of mouse / rat antibodies using a modernized version of the traditional CDR grafting technique: o Well recognized expertise knowledge in humanization. o Sequence analysis and in silico design of VH and VL humanized versions using a human germline approach. o Sequence optimization of CDRs to improve developability / manufacturability of lead candidates and improve affinity / selectivity.• Provide as a service the possibility of the humanized constructs to be synthesized, cloned, expressed, purified and tested using CRO facilities: o Identify project risks at the onset of the program. o Identify and select trusted CRO facilities that have the right skill set and knowledge to achieve project deliverables and timelines. o Plan program activities with input from CROs and oversee the execution in a virtual lab.• Provide as a service sequence optimization of fully human antibodies to improve developability / manufacturability by germlining and elimination of potentially problematic amino acid single residues or motifs. • Provide as a service project plan for antibody projects from discovery to preclinical development and oversee if necessary the progression of the project.• Due diligence and evaluation of antibody technologies.• Provide expert advice on broad antibody engineering aspects; especially choice of isotype, affinity maturation, effector function and FcRn binding.• Contact: legerol.consulting@gmail.com
  • Vetoquinol S.A.
    Biotechnology Research Manager
    Vetoquinol S.A. Jan 2022 - Feb 2023
    Lure, Bourgogne-Franche-Comté, France
  • Vetoquinol S.A.
    Biotechnology Research Manager
    Vetoquinol S.A. Jun 2017 - Jan 2022
    Paris, Île-De-France, France
    Responsible for discovering biotech products for small and large animals in particular monoclonal antibodies to be used in pets for treating skin diseases
  • Merck Serono
    Head Of Antibody Engineering
    Merck Serono Sep 2008 - Jun 2013
    Geneva Area, Switzerland
    • Antibody engineering processes: sequence optimization for improved manufacturability, affinity maturation by semi-rational design and humanization by CDR-grafting.• Project team member on internal antibody projects from discovery to preclinical development.• Project team member on external collaborations on antibody or "nanobody" related projects. • Due diligence and evaluation of external in-licensing opportunities.• Line-management responsibilites.• Group leadership
    View
  • Novimmune
    Head Of Antibody Engineering / Project Manager
    Novimmune Apr 2004 - Aug 2008
    Geneva Area, Switzerland
    • Responsible for the engineering of recombinant fully human antibodies derived from the phage display DiversityTrap platform: NI-0801, anti-human CXCL10 (IP10) and NI-0501, anti-human interferon gamma. • Responsible for the engineering of recombinant fully human antibodies derived from BMS/Medarex UltiMAb transgenic mouse system: NI-0401, anti-human CD3-epsilon; NI-1401 cross-reactive anti-human IL-17A&F partnered with Genentech and NI-1201, anti-human IL6-receptor.• Humanization by CDR-grafting of mouse antibodies, most noticeably NI-0101, a monoclonal antibody drug candidate targeting Toll-like receptor-4 (TLR4) presently undergoing dosing in a phase I clinical trial.• Engineering of Fc to enhance binding to human Fc-gamma-Receptor II.• Project management and line management responsibilities.
    View
  • Pierre Fabre
    Group Leader, Antibody Engineering Group, Centre D'Immunologie Pierre Fabre (Cipf)
    Pierre Fabre Dec 1997 - Mar 2004
    Saint Julien En Genevois, France
    • Establish an Antibody Engineering group at CIPF whose director was Dr. Jean-Yves Bonnefoy.• Responsible for the engineering and development of recombinant antibodies for use in human cancer therapy.• Humanisation by CDR-grafting of an anti-IGF-1 receptor mouse monoclonal antibody, F50035, which has being licensed by Merck & Co.• Line-managment responsabilites.
    View
  • Mrc Technology
    Group Leader, Antibody Engineering Group
    Mrc Technology Aug 1992 - Nov 1997
    Mill Hill, London, Uk
    • The Antibody Engineering Group led by Mary M. Bendig was established at the MRC Collaborative Centre to exploit MRC-patented technologies for humanisation by CDR-grafting and MRC-CAT-patented technologies for phage display.• Responsible for humanisaton by CDR-grafting of mouse monoclonal antibodies and most noticeably of the anti-alpha4 integrin antibody, Natalizumab, co-marketed by Biogen Idec and Elan as Tysabri for multiple sclerosis treatment.• Construction and screening of phage antibody libraries derived from the lymph nodes of human cancer patients for anti-tumor cell specific scFvs.• Line-management responsabilities.
    View
  • Institute Of Cancer Research
    Research Fellow, Department Of Molecular Immunology
    Institute Of Cancer Research Dec 1989 - Jul 1992
    Sutton, United Kingdom
    • Gain of new advances in molecular biology techniques related to antibody engineering; PCR-cloning and DNA sequencing of variable genes, construction of scFv formats, expression of recombinant antibody and antibody fragments.
    View
  • The Institute Of Cancer Research
    Phd Student
    The Institute Of Cancer Research Oct 1986 - Nov 1989
    Sutton, Surrey, Uk
    • Characterization of the serological anti-tumor response to a chemically-induced rat sarcoma; idiotypic network• Rat hybridoma technology: immunisation of rats via the Peyer's patches, obtention of rat x rat hybridomas• Antibody characterization; purification by affinity chromatography, SDS-PAGE• Assay development: radio-immunassays, cellular assays• Purification, characterization and identification of a chemically-induced tumor antigen in syngeneic rats
    View
  • Royal Free Hampstead Nhs Trust
    Research Assistant, Department Of Haematology
    Royal Free Hampstead Nhs Trust Nov 1985 - Sep 1986
    Hampstead, London, Uk
    • Position in the bone marrow transplantation unit headed by Dr. H. Grant Prentice and the research directed by Dr. Malcolm K. Brenner• Evaluation of the effect of interleukin-2 on the killer cell function of natural killer cells after T-cell depleted bone marrow transplantation
    View
  • Sanofi
    Trainee, Clin-Midy Sanofi, Department Of Immunology
    Sanofi Feb 1985 - Oct 1985
    Montpellier, France
    • Project was to compare two different techniques of human T-cell depletion from peripheral blood and bone marrow; complement-mediated cytolysis and immunotoxin T101 ricin chain A conjugate-mediated depletion (T101 antibody is directed against mature human T cells)• Immunotoxin T101 ricin chain A project headed by Frank K. Jansen and under the supervision of Dr. Jean-Marie Derocq
    View

Olivier Léger Skills

Antibodies Immunology Drug Discovery Assay Development Biopharmaceuticals Biotechnology Drug Development Immunoassays Biochemistry Protein Chemistry Molecular Cloning Antibody Engineering Antibody Humanization Monoclonal Antibodies Protein Expression Sds Page Pharmaceutical Industry Purification Cro

Olivier Léger Education Details

Frequently Asked Questions about Olivier Léger

What company does Olivier Léger work for?

Olivier Léger works for Tridek-One

What is Olivier Léger's role at the current company?

Olivier Léger's current role is Independent consultant in the field of Antibody Engineering.

What schools did Olivier Léger attend?

Olivier Léger attended University Of London, Université Montpellier Ii, France.

What are some of Olivier Léger's interests?

Olivier Léger has interest in Gardening, Travelling, New Technologies, Sports, Pets.

What skills is Olivier Léger known for?

Olivier Léger has skills like Antibodies, Immunology, Drug Discovery, Assay Development, Biopharmaceuticals, Biotechnology, Drug Development, Immunoassays, Biochemistry, Protein Chemistry, Molecular Cloning, Antibody Engineering.

Who are Olivier Léger's colleagues?

Olivier Léger's colleagues are Daniela Chmiest-Silin, Phd, Mariangela Corsi, Dr. Holger Ottleben, Guillaume Even.

Not the Olivier Léger you were looking for?

View similar profiles

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.